Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.
about
Animal models for Ebola and Marburg virus infectionsEmerging targets and novel approaches to Ebola virus prophylaxis and treatmentDelayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaquesEbola haemorrhagic feverIn vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virusAntiviral effects of antisense morpholino oligomers in murine coronavirus infection modelsPre-symptomatic diagnosis and treatment of filovirus diseasesStandardization of the filovirus plaque assay for use in preclinical studiesMouse models for filovirus infectionsDevelopment of RNA Aptamers Targeting Ebola Virus VP35Ebola Viral Disease in West Africa: A Threat to Global Health, Economy and Political StabilityProgress towards the treatment of Ebola haemorrhagic fever.Updates in diagnosis and management of Ebola hemorrhagic fever.Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Development and characterization of a mouse model for Marburg hemorrhagic feverPathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques.Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex.A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new groundAre we any closer to combating Ebola infections?Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challengeFilovirus replication and transcription.Treatment of ebola virus disease.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in miceAn upstream open reading frame modulates ebola virus polymerase translation and virus replication.Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primatesMonovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies.Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infectionDNA and RNA derivatives to optimize distribution and deliveryPostexposure treatment of Marburg virus infectionTherapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation.Development of a model for marburgvirus based on severe-combined immunodeficiency mice.Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections.Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers.A Syrian golden hamster model recapitulating ebola hemorrhagic fever.Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agentsManaging potential laboratory exposure to ebola virus by using a patient biocontainment care unit.Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection
P2860
Q21131118-FB83D30E-DC47-4946-89A7-0DDF9C096008Q24597625-5388D7BF-887F-45F8-A35F-9B6D997247D8Q24612811-08FF87D0-2015-4898-AA9B-C3AA3766DDAFQ24629338-77C2ED7F-9C29-4323-9A84-C9B6C47C04E9Q24678543-47E18B63-6608-4AC6-B625-80497D8F24AEQ24682873-9B945E04-DD33-4CF4-A029-364D77D44CADQ26823831-6D233F68-0202-4FC7-BA39-76FBBE9921A5Q27000207-EE98E42A-0A54-42C5-BC4A-D6E92949645EQ27011569-075555DC-BDD8-402B-99A7-3F1F25DCB604Q27680060-27C7636E-0EBC-4924-AF26-07F01BA8D26CQ30148821-E94FF8EE-61F3-4AFB-98CC-93E20DFB8375Q30230272-8ACCD510-821D-4102-A030-E602BE37C1CFQ30238537-3A187671-907E-47F8-A4ED-3EC534D11FA4Q30252022-A3B9B1A0-999E-47E6-839F-C8FD658E0158Q33384111-9375787E-05EB-4C56-B127-89884DDEABF0Q33404944-D464CFD7-DC4E-481D-99CA-2FB5790F137CQ33857479-BB76CB69-EEB1-404C-99AA-92C009E18659Q33950888-3E4BE051-90EA-4CF9-A0D4-B656D200679AQ34022601-BF978777-A8C1-4019-9B37-51E61010DAB6Q34361120-26F7DFD7-77ED-4877-BC3A-1BD19C2DAE91Q34375243-133D164D-7744-4778-B0FC-23AEF3AC2F3BQ34460182-92034F8B-3695-412B-8B71-073D84593B2FQ34463780-5BCDB389-AD43-4F01-AA7D-3F36A5A3A5A1Q34509643-5CF3DC17-AB70-4676-98AB-8D0B3C848F46Q34574867-20746E99-89E8-44C1-BDAE-52B98BD8D703Q34589949-35F91C6B-FA9A-48D7-AB2B-C1E8CC4E3DCCQ34774783-19923479-CF08-426C-98CF-145620D6DD89Q34971349-DAE5E9DC-582E-4BAF-B639-63F4ED251C20Q35202880-B9BC86CA-06EC-4369-90BB-D3BE8867F806Q35842390-E4B1A3DA-DEFF-44C4-ABA9-B34C87481CA5Q35858691-7806C5AB-EE39-42AF-9B5C-D13F0826EA9BQ35877126-FF8C6C0F-A851-46EC-B338-3A5D05CE227FQ36011859-9302BE24-D5C2-4926-B6DE-9B8F5429640EQ36310674-95D8004C-C7D4-49BF-9D59-090A17E4BB56Q36432717-885CDEFD-71EF-4AC4-BBEA-3CB7166D04A8Q36482804-BA70AC51-5BE1-42CC-BC6F-3FA0BCF335C7Q36495558-5B9B4361-E07E-4EB3-BF82-C052F54C03B0Q36925191-120F4289-32C5-4D86-8594-E9F327D054B6Q37009322-10E0E628-2B33-40C8-9B4E-50ABF67CF58FQ37190830-AE00C08C-EA35-46F0-A7E4-99AE27FB7E99
P2860
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Gene-specific countermeasures ...... diamidate morpholino oligomers
@nl
Gene-specific countermeasures ...... iamidate morpholino oligomers.
@ast
Gene-specific countermeasures ...... iamidate morpholino oligomers.
@en
type
label
Gene-specific countermeasures ...... diamidate morpholino oligomers
@nl
Gene-specific countermeasures ...... iamidate morpholino oligomers.
@ast
Gene-specific countermeasures ...... iamidate morpholino oligomers.
@en
altLabel
Gene-Specific Countermeasures ...... diamidate Morpholino Oligomers
@en
prefLabel
Gene-specific countermeasures ...... diamidate morpholino oligomers
@nl
Gene-specific countermeasures ...... iamidate morpholino oligomers.
@ast
Gene-specific countermeasures ...... iamidate morpholino oligomers.
@en
P2093
P2860
P50
P1433
P1476
Gene-specific countermeasures ...... diamidate morpholino oligomers
@en
P2093
Dana L Swenson
David A Stein
Donald K Nichols
Kelly L Warfield
M Javad Aman
Robert Blouch
William D Pratt
P2860
P356
10.1371/JOURNAL.PPAT.0020001
P407
P577
2006-01-13T00:00:00Z